About NDC-1308 For Inducing Remyelination


R
A new drug with the potential to induce remyelination, the process for restoring and repairing the myelin sheath in demyelinating diseases including multiple sclerosis (MS), transverse myelitis and osmotic demyelination syndrome.
NDC-1308

How the Body Makes Myelin


Oligodendrogenesis:

the body’s natural process for forming mature, myelinating oligodendrocytes leading to myelin sheaths. The process start from oligodendrocyte progenitor cells (OPCs) that are located throughout the central nervous system (CNS).

oligodendrogensis picture

NDC-1308 Induces the Body’s Natural System for Oligodendrogenisis


NDC-1308 is currently in late preclinical development, it is designed to address one of the root causes of demyelinating disease by inducing oligodendrocyte progenitor cells (OPCs) – the precursors of oligodendrocytes – to mature into oligodendrocytes, the cells that synthesize and maintain the myelin sheath.


=

Step 1:

Oligodendrocyte progenitor cells (OPCs) are present but quiescent

=

NDC-1308

Designed to up-regulate key genes to induce remyelination

=

Step 2:

Gene activated by NDC-1308
Inducing Oligodendrogenisis


=

Step 3:

Pre-oligodendrocytes become pre-myelinating oligodendrocytes
=

Step 4:

Pre-myelinating oligodendrocytes become myelinating oligodendrocytes

A Multiple Target Approach


The unique remyelinating activity of NDC-1308 comes from its ability to significantly up-regulate key genes necessary for OPC differentiation into mature oligodendrocytes.

NDC 1308 up regulates

ENDECE logo
Developing new drugs for diseases with limited or non-existent treatment options.
TO REQUEST MORE INFORMATION GO TO:
www.endece.com/contact